The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases

The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases

<p dir="ltr"><strong>Introduction: </strong></p><p dir="ltr"><strong></strong>PD-1 is programmed death receptor 1 belonging to the CD28 family of receptors. Immune cells have this receptor on their surface. PD-L1 allows cancer cells to av...

Full description

Bibliographic Details
Main Authors:	Dominika Katarzyna Madras, Agata Agnieszka Rocka, Klaudia Daria Szumna, Patryk Piotr Jasielski, Faustyna Piędel
Format:	Article
Language:	English
Published:	Kazimierz Wielki University 2020-04-01
Series:	Journal of Education, Health and Sport
Subjects:	programmed death receptor-1 (pd-1) programmed death receptor ligand-1 (pd-l1) immunotherapy oncology autoimmunology infectious diseases
Online Access:	https://apcz.umk.pl/czasopisma/index.php/JEHS/article/view/29711

Similar Items

Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer
by: Andrzej Kowalski, et al.
Published: (2021-07-01)

Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids
by: Mingbiao LI, et al.
Published: (2016-12-01)

Progress of research on PD-1/PD-L1 in leukemia
by: Huizhen Cao, et al.
Published: (2023-09-01)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
by: Wei Shi, et al.
Published: (2023-05-01)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
by: Yuedi Zhang, et al.
Published: (2022-06-01)

Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas
by: Kazuhiko Hashimoto, et al.
Published: (2021-07-01)

PD-1 and PD-L1 Expression in Indian Women with Breast Cancer
by: Kishan R. Bharadwa, et al.
Published: (2022-01-01)

The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
by: Sajad Najafi, et al.
Published: (2023-05-01)

The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology
by: Sandra Schöniger, et al.
Published: (2022-10-01)

PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
by: Margarita Udall, et al.
Published: (2018-02-01)

Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy
by: Mohammadsaleh Jahangir, et al.
Published: (2022-12-01)

Role of the PD-1/PD-L1 Dyad in the Maintenance of Pancreatic Immune Tolerance for Prevention of Type 1 Diabetes
by: Marika Falcone, et al.
Published: (2020-08-01)

Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1
by: Keywan Mortaezaee, et al.
Published: (2023-07-01)

PD-1 and PD-L1 expression in rare lung tumors
by: Marton Gyulai, et al.
Published: (2023-05-01)

Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis
by: Fabio Scirocchi, et al.
Published: (2022-11-01)

Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment
by: Suxia Geng, et al.
Published: (2022-08-01)

Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies
by: Ismael Rodriguez, et al.
Published: (2023-09-01)

Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer
by: Magdalena Bojko, et al.
Published: (2024-04-01)

Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters
by: Anoushika Mehan, et al.
Published: (2022-03-01)

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience
by: Fengze Sun, et al.
Published: (2022-03-01)

PROTECTION OF T-LYMPHOCYTES VIA PD-1 RECEPTOR: NEW MOLECULAR MECHANISM OF CANCER IMMUNOTHERAPY
by: Sandor Szabo
Published: (2019-12-01)

Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis
by: Mohammad Reza Javan, et al.
Published: (2016-08-01)

Immunohistochemical Expression of Programmed Cell Death Ligand 1 (PD-L1) in Human Cutaneous Malignant Melanoma: A Narrative Review with Historical Perspectives
by: Gerardo Cazzato, et al.
Published: (2023-06-01)

Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations
by: Ling JIANG, et al.
Published: (2021-09-01)

Comparison of Immune Checkpoint Molecules <i>PD-1</i> and <i>PD-L1</i> in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence
by: Wei Yu, et al.
Published: (2022-02-01)

Computational Approaches Drive Developments in Immune-Oncology Therapies for PD-1/PD-L1 Immune Checkpoint Inhibitors
by: Patrícia S. Sobral, et al.
Published: (2023-03-01)

Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients
by: Pawłowska A, et al.
Published: (2020-10-01)

PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy
by: Li Chen, et al.
Published: (2022-05-01)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
by: Fenglong Bie, et al.
Published: (2022-02-01)

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
by: Young Wha Koh, et al.
Published: (2017-03-01)

PD-1/PD-L1 and DNA Damage Response in Cancer
by: Mateusz Kciuk, et al.
Published: (2023-02-01)

Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer
by: Witold Zgodzinski, et al.
Published: (2018-04-01)

Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies
by: Ryotaro Ohkuma, et al.
Published: (2021-12-01)

The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy
by: Keywan Mortezaee, et al.
Published: (2023-06-01)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
by: Ze Xiang, et al.
Published: (2022-05-01)

Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies
by: Keywan Mortezaee, et al.
Published: (2023-02-01)

Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia
by: Yingying Wang, et al.
Published: (2018-04-01)

Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy
by: Rilan Bai, et al.
Published: (2022-05-01)

Anti-PD-(L)1 therapy of non-small cell lung cancer–A summary of clinical trials and current progresses
by: Keywan Mortezaee, et al.
Published: (2023-03-01)

Development and Validation of a Biolayer Interferometry Method for Determination of Human Anti-PD-1 Monoclonal Antibody Concentration in Cynomolgus Serum
by: K. V. Ulyanova, et al.
Published: (2020-12-01)